37 results on '"Muscat, Andrea"'
Search Results
2. Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium
3. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
4. 7 CLADIN: CLADribine and INnate immune responses in multiple sclerosis
5. A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors
6. 2304 CLADIN: CLADribine and INnate Immune responses in Multiple Sclerosis
7. Genetic variation affecting DNA methylation and the human imprinting disorder, Beckwith-Wiedemann syndrome
8. STING is silenced by DNA methylation in primary brain tumors and is rescued by methyltransferase inhibition (P13-9.004)
9. Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition
10. BIOM-20. TUMOR-INTRINSIC AND PERIPHERAL FEATURES ASSOCIATE WITH SURVIVAL AFTER POLIO VIROTHERAPY IN RECURRENT GBM
11. EPCO-12. STING IS SILENCED IN GBM BY PROMOTER METHYLATION THAT IS ESTABLISHED BY TISSUE OF ORIGIN
12. EPCO-21. STING PROMOTER EPIGENETIC SILENCING IN GLIOBLASTOMA
13. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells
14. Rhabdoid tumour: a malignancy of early childhood with variable primary site, histology and clinical behaviour
15. Caspase-8 Levels Correlate With the Expression of Signal Transducer and Activator of Transcription 1 in High-Grade But Not Lower Grade Neuroblastoma
16. Caspase 8 is absent or low in many ex vivo gliomas
17. Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: the phase II NEONAB trial—clinical outcomes and molecular determinants of response
18. Additional file 2: of Genetic variation affecting DNA methylation and the human imprinting disorder, Beckwith-Wiedemann syndrome
19. Additional file 1: of Genetic variation affecting DNA methylation and the human imprinting disorder, Beckwith-Wiedemann syndrome
20. Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial—Clinical outcomes and molecular determinants of response
21. ATIM-27. INTRATUMORAL ADMINISTRATION OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF MUTATIONAL RESPONSE CORRELATES
22. The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection
23. Glioma Through the Looking GLASS: the Glioma Longitudinal Analysis consortium, molecular evolution of diffuse gliomas
24. Recurrent Glioblastoma Treated with Recombinant Poliovirus
25. The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection
26. Low-dose histone deacetylase inhibitor treatment leads to tumor growth arrest and multi-lineage differentiation of malignant rhabdoid tumors
27. Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors
28. Mutational analysis of matched initial and recurrent TP53 WT primary GBM.
29. A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors.
30. SMARCB1 MANIPULATION AND EPIGENETIC PROFILING IN ATYPICAL TERATOID RHABDOID TUMORS (ATRTs) PROVIDES NOVEL INSIGHTS INTO TUMOR ETIOLOGY
31. High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival
32. Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors
33. Methods for the analysis of histone H3 and H4 acetylation in blood
34. High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival
35. Imprinted CDKN1C Is a Tumor Suppressor in Rhabdoid Tumor and Activated by Restoration of SMARCB1 and Histone Deacetylase Inhibitors
36. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells
37. Imprinted CDKN1C Is a Tumor Suppressor in Rhabdoid Tumor and Activated by Restoration of SMARCB1 and Histone Deacetylase Inhibitors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.